Core Viewpoint - The Tianhong Nonferrous Metals ETF (159157) has shown strong performance, leading the market in trading volume and net inflows, indicating a growing interest in the nonferrous metals sector driven by various market dynamics [1][2][3]. Group 1: ETF Performance - As of February 24, the Tianhong Nonferrous Metals ETF reached a record size of 2.159 billion yuan and a total of 2.173 billion shares, marking new highs since its inception [2]. - The ETF recorded a turnover of 9.37% with a trading volume of 208 million yuan, ranking first among similar products in the Shenzhen market [1]. - Over the past week, the ETF has seen continuous net inflows, with a peak single-day inflow of 269 million yuan, totaling 1.067 billion yuan in net inflows [3]. Group 2: Market Trends - The CSI Industrial Nonferrous Metals Theme Index, which the ETF tracks, surged by 5.40%, with notable increases in constituent stocks such as Chihong Zn & Ge (up 10.01%), Tin Industry Co. (up 10.00%), and Northern Rare Earth (up 9.99%) [1]. - The ETF focuses on key metals like copper, aluminum, and rare earths, covering 30 leading companies in the industry, thus providing a strategic investment opportunity amid AI-driven, strategic resource, and cyclical upturn trends [4]. Group 3: Relevant Events - The Trump administration plans to utilize AI to set reference prices for critical minerals, including germanium, gallium, antimony, and tungsten, aiming to establish a global metal trading group [5]. - This initiative is intended to attract allies and protect domestic mining companies through transparent pricing, although the effectiveness of AI pricing and international cooperation remains under scrutiny [5]. Group 4: Institutional Insights - Citic Securities has noted significant fluctuations in gold prices, attributing them to market concerns over the Federal Reserve's independence and geopolitical uncertainties, which may affect the broader precious and nonferrous metals market outlook [6].

Core Insights - The Shanghai Gold ETF (159830) has seen a turnover of 5.94% and a transaction volume of 221 million yuan as of February 13, 2026, with a net inflow of 9.92 million yuan [1] - International gold prices have risen nearly 4% during the holiday period, surpassing the 5200 USD mark, driven by increased market risk aversion due to new tariff policies and economic data from the U.S. [2] - UBS maintains a positive outlook on gold, projecting a target price of 6200 USD per ounce in the coming months, citing geopolitical risks and continued central bank purchases as key drivers [2] Product Highlights - The Shanghai Gold ETF (159830) has a total management and custody fee of 0.30%, which is lower than the average fee of 0.60% for most gold ETFs [1] - The ETF has reached a new high in shares since its inception, indicating strong investor interest and confidence [1] Related Products - The Shanghai Gold ETF (159830) is linked to off-market funds, including Connect Fund A (014661) and Connect Fund C (014662) [1] - Other ETFs mentioned include various sector-focused funds such as the Technology ETF, Biopharmaceutical ETF, and Aerospace ETF, indicating a diverse range of investment opportunities in the market [3][4]

Core Insights - The ChiNext ETF Tianhong (159977) has seen significant trading activity, with a transaction volume of 117 million yuan and a strong increase of 3.06% in the tracked ChiNext Index (399006) [1] - The ChiNext ETF Tianhong (159977) has experienced a substantial growth of 11.76 million shares over the past six months, with a total net inflow of 44.08 million yuan in the last four days [2] Product Highlights - The ChiNext ETF Tianhong (159977) offers several advantages: it bundles a variety of ChiNext stocks, has a daily price fluctuation limit of ±20%, requires no asset or investment duration for account opening, and allows for convenient trading like stocks [3] Industry Events - The Shanghai government highlighted its strengths in the artificial intelligence sector, including collaborative industrial clusters, large market scenarios, talent supply, and a complete financial system. Shanghai accounts for nearly 10% of the national computing power and has launched various initiatives to support AI development [4] Institutional Views - Guotai Junan Securities noted that the market remains in a high volatility state before the Spring Festival, suggesting that the next wave of market activity will likely be based on logic rather than sentiment. They anticipate a potential resurgence of technology growth stocks after the Spring Festival [5]

Core Viewpoint - The innovative drug ETF Tianhong (517380) has shown strong performance, with significant inflows and positive market reactions to earnings reports from key companies in the sector, particularly Eli Lilly's impressive revenue growth driven by weight loss drugs [2][3]. Group 1: ETF Performance - As of February 5, 2026, the innovative drug ETF Tianhong (517380) recorded a transaction volume of 4.9451 million yuan, with the tracked index HSSSHID rising by 0.11% [1]. - Over the past 20 trading days, the innovative drug ETF Tianhong (517380) attracted a total of 395 million yuan [2]. Group 2: Company Highlights - Eli Lilly reported a 43% year-over-year increase in Q4 revenue, reaching 19.29 billion dollars, with adjusted earnings per share of 7.54 dollars, both exceeding market expectations [2]. - Eli Lilly's weight loss drugs, Mounjaro and Zepbound, generated over 11.6 billion dollars in sales, accounting for more than 60% of total revenue [2]. - The company projects full-year revenue for 2026 to be between 80 billion and 83 billion dollars, with adjusted earnings per share expected to be between 33.50 and 35 dollars, also surpassing market forecasts [2]. Group 3: Industry Insights - Donghai Securities anticipates that the innovative drug sector will enter a phase of accelerated profit realization by 2025, with companies like Nocare and Rongchang Biopharma turning profitable [3]. - The core drivers of this growth are rapid commercialization of products and business development (BD) collaborations, with companies leveraging both to enhance profitability [3]. - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product commercialization supported by healthcare insurance being a fundamental growth driver [3].

Core Viewpoint - The Shanghai Gold ETF (159830) has reached new highs in both scale and shares, indicating strong investor interest and confidence in gold as a safe-haven asset amid recent market volatility [2][3]. Fund Performance - As of February 4, 2026, the Shanghai Gold ETF (159830) recorded a turnover rate of 8.76% with a transaction volume of 279 million yuan [1]. - The latest scale of the Shanghai Gold ETF is 3.585 billion yuan, with a total of 316 million shares, both marking all-time highs since its inception [2]. - The fund has seen a net inflow of 386 million yuan recently, reflecting positive investor sentiment [3]. Product Highlights - The management fee for the Shanghai Gold ETF is 0.25%, and the fund custody fee is 0.05%, both lower than the average for similar products, making it an attractive option for investors [4]. - The ETF supports T+0 trading, providing flexibility for investors [4]. Market Events - International gold prices have rebounded significantly, increasing nearly 700 USD over three days, from a low of 4402 USD/ounce to 5091 USD/ounce [5]. Institutional Insights - Guotai Junan Securities suggests that the long-term outlook for gold remains supported, viewing the recent price drop as a technical adjustment rather than the end of a long-term bull market. They anticipate a return to a healthier upward trend for gold prices, driven by reduced speculative sentiment and lower leverage levels [6]. - The ongoing restructuring of the global monetary system and continued central bank purchases of gold are expected to sustain the long-term bullish trend for gold [6].

Group 1: ETF Performance - As of January 21, the Medical Equipment ETF (159873) saw a net subscription of 3 million units, with a turnover rate of 8.04% and a transaction volume of 18.88 million yuan [1] - The Medical Equipment ETF reached a new high with a total size of 379 million units [1] - The Medical Equipment ETF has experienced continuous net inflows over the past 10 days, totaling 119 million yuan [1] Group 2: Innovation Drug ETF Highlights - The Innovation Drug ETF Tianhong (517380) achieved a new size of 1.88 billion yuan and a total of 2.36 billion units, both marking new highs since its inception [2] - The Innovation Drug ETF has seen continuous net inflows for 12 days, accumulating 426 million yuan [3] Group 3: Market Trends and Events - A new guideline was released by the National Healthcare Security Administration on January 20, focusing on pricing for surgical robots and other medical services, establishing 37 pricing projects and 5 additional items [6] - The JPM 2026 conference highlighted the strength of Chinese innovative drugs, with significant collaborations between Chinese companies and multinational giants, indicating a shift from asset export to global participation [7] Group 4: Institutional Insights - According to Founder Securities, the implementation of the new pricing guideline will promote the clinical adoption of innovative technologies and drive demand for terminal equipment and surgical assistance [8] Group 5: Product Features - The Medical Equipment ETF (159873) has a high content of brain-computer interface stocks, accounting for over 19%, and includes nearly 80% of stocks from the Sci-Tech Innovation Board and the Growth Enterprise Market [4]

Group 1 - The core point of the news is the significant growth of the Tianhong ChiNext ETF (159977), which has seen a substantial increase in both subscription and scale, indicating strong investor interest in the ChiNext index and related sectors [1][2][3]. Group 2 - As of January 19, 2026, the Tianhong ChiNext ETF (159977) recorded over 20 million subscriptions, with a transaction volume of 89.24 million yuan, while the ChiNext index (399006) rose by 0.53% [1]. - In the past month, the Tianhong ChiNext ETF (159977) experienced a scale increase of 55.79 million yuan, and over the last six months, its shares grew by 1.243 billion shares, showcasing significant growth [2]. - The Tianhong ChiNext ETF (159977) tracks the ChiNext index and focuses on strategic emerging industries such as high-end manufacturing, photovoltaics, and new energy vehicles, benefiting from a 20% fluctuation limit, which provides high elasticity advantages [3].

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative drug ETF Tianhong (517380) and the medical device ETF (159873), both reaching new highs in terms of scale and shares [1][2] - As of January 13, the innovative drug ETF Tianhong (517380) has a scale of 1.807 billion yuan and 2.162 billion shares, marking a record high since its inception [1] - The innovative drug ETF has seen a net inflow of 264 million yuan over the past six days, indicating strong investor interest [1] Group 2 - The medical device ETF (159873) also reached new highs in scale and shares as of January 13, with a net inflow of 26.503 million yuan over the past four days, leading its category with a net flow rate of 28.22% [2] - The medical device ETF has a high concentration in brain-computer interface stocks, accounting for over 19%, and is expected to benefit from domestic innovation, accelerated exports, and new technologies [2] - WuXi AppTec's stock price reached a new high, with a projected revenue of 45.456 billion yuan for 2025, reflecting a year-on-year growth of 15.84% [3][4] Group 3 - WuXi AppTec's adjusted net profit is expected to be 14.957 billion yuan for 2025, a year-on-year increase of 41.33%, driven by its focus on a unique "integrated, end-to-end" CRDMO business model [3] - The company is expected to maintain strong performance in 2026, supported by a solid business foundation and a clear strategic path [4] - The biopharmaceutical industry is anticipated to face external uncertainties, but WuXi AppTec's comprehensive service capabilities and enhanced quality systems are seen as valuable certainties in the market [4]

Core Insights - The medical device ETF (159873) has shown strong trading activity with a turnover of 26.84% and a transaction volume of 36.34 million yuan, while the underlying index, the CSI All Share Healthcare Equipment and Services Index (H30178), increased by 1.09% [1] - The innovative drug ETF Tianhong (517380) also performed well, with a turnover of 5.36% and a transaction volume of 95.97 million yuan, tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index (HSSSHID), which rose by 2.21% [1] - Both ETFs reached new highs in terms of scale and shares as of January 13, 2026, with the medical device ETF achieving a record scale and share, while the innovative drug ETF reached a scale of 1.807 billion yuan and 2.162 billion shares [2][3] Fund Flows - The medical device ETF (159873) has seen a net inflow of 26.50 million yuan over the past four days [1] - The innovative drug ETF Tianhong (517380) experienced a net inflow of 264 million yuan over the last six days [3] Product Highlights - The medical device ETF (159873) has a high concentration in brain-computer interface technology, accounting for over 19%, with nearly 80% of its components from the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - The innovative drug ETF Tianhong (517380) targets opportunities in the innovative drug sector, benefiting from the concentration of top component stocks like WuXi AppTec and Hengrui Medicine, alongside the growth in BD transactions and breakthroughs in AI drug development [4] Industry Events - Qiangnao Technology, a brain-computer interface company, has submitted a confidential IPO application for listing on the Hong Kong Stock Exchange, potentially becoming the first listed company in China's brain-computer interface sector [4] - The company has completed approximately 2 billion yuan in financing, marking the second-largest financing event globally in the brain-computer interface field, excluding Neuralink [4][5] Institutional Perspectives - Analysts from Changcheng Guorui Securities view brain-computer interfaces as a forward-looking direction under the 14th Five-Year Plan, with several recommended industry standards being established to promote technological standardization and clinical registration processes [5]

Group 1 - The CRO and innovative drug sectors are experiencing strong gains, with stocks like Rongchang Biopharma A-shares and H-shares, WuXi AppTec, and Sanofi rising by 17%, 9%, 7.9%, and 7.2% respectively, leading to a 3.5% increase in the Tianhong Innovative Drug ETF [1] - The Tianhong Innovative Drug ETF (517380) is the only ETF tracking the Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50 Index, focusing on 50 actively traded innovative drug and CXO companies with high R&D investment [1] - The ETF has seen a net inflow of 207 million yuan over the past five days, indicating strong investor interest [1] Group 2 - The 44th JPMorgan Global Healthcare Conference is set to take place, with over 20 domestic innovative drug companies confirmed to participate, including WuXi AppTec and several others [1] - WuXi AppTec is projected to achieve a profit of 19.151 billion yuan in 2025, representing a year-on-year increase of 103%, with Q4 net profit expected to reach 7.075 billion yuan, a quarter-on-quarter increase of 101% [1] - The sixth batch of national centralized procurement for high-value medical consumables is about to open for bidding, including 12 types of medical consumables [2] Group 3 - The medical device ETF (159873) has a significant focus on brain-machine interfaces, accounting for over 19% of its composition, indicating strong technological attributes [2] - The ETF's components include a high proportion of stocks from the Sci-Tech Innovation Board and the Growth Enterprise Market, nearly 80%, suggesting a robust growth potential [2] - The industry outlook for 2026 remains positive, with a focus on innovation, international expansion, and recovery in challenging markets, particularly in the CXO and upstream supply chain sectors [2]